Overview

Evaluation of the Efficacy and Safety of a 4-month Daily Regimen (2HZPM/2HPM) for Treatment of Pulmonary TB

Status:
Not yet recruiting

Trial end date:
2024-12-31

Target enrollment:

Participant gender:

Summary

The development of efficacious, safe, and shorter treatment regimens could significantly improve TB management and treatment success rates. This prospective, 3-year, single arm study is to evaluate the efficacy and safety of a short-course, 4-month regimen including isoniazid(H), pyrazinamide(P), rifapentine (P), and moxifloxacin(M) (2HZPM/2HPM) for the treatment of drug-susceptible, pulmonary tuberculosis, and compared with a historical control group receiving the standard six-month regimen.

Phase:

Phase 3

Details

Lead Sponsor:

Kaohsiung Veterans General Hospital.

Collaborators:

Centers for Disease Control, Taiwan
Chang Gung Memorial Hospital
National Taiwan University
Taipei Veterans General Hospital, Taiwan

Treatments:

Moxifloxacin
Rifampin
Rifapentine